Page 20 - Read Online

Page 12 of 13 Giovanis et al. Hepatoma Res 2018;4:10 I http://dx.doi.org/10.20517/2394-5079.2018.21

28. Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients
with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol 2017;67:999-1008.
29. Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladron de Guevara L,
Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL. Regional differences in sorafenib-treated
patients with hepatocellular carcinoma: GIDEON observational study. Liver Int 2016;36:1196-205.
30. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Camma C, Colombo M; SOFIA (SOraFenib Italian Assessment)
study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology
2011;54:2055-63.
31. Ponziani FR, Bhoori S, Germini A, Bongini M, Flores M, Sposito C, Facciorusso A, Gasbarrini A, Mazzaferro V. Inducing tolerability
of adverse events increases sorafenib exposure and optimizes patient’s outcome in advanced hepatocellular carcinoma. Liver Int
2016;36:1033-42.
32. Reig M, Torres F, Rodriguez-Lope C, Forner A, NLL, Rimola J, Darnell A, Rios J, Ayuso C, Bruix J. Early dermatologic adverse events
predict better outcome in HCC patients treated with sorafenib. J Hepatol 2014;61:318-24.
33. Bettinger D, Schultheiss M, Knuppel E, Thimme R, Blum HE, Spangenberg HC. Diarrhea predicts a positive response to sorafenib in
patients with advanced hepatocellular carcinoma. Hepatology 2012;56:789-90.
34. Otsuka T, Eguchi Y, Kawazoe S, Yanagita K, Ario K, Kitahara K, Kawasoe H, Kato H, Mizuta T; Saga Liver Cancer Study Group. Skin
toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res 2012;42:879-86.
35. Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Am J Clin Oncol 2013;36:319-24.
36. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete
S, Tonini G. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.
Oncologist 2010;15:85-92.
37. Kudo M. Locoregional therapy for hepatocellular carcinoma. Liver Cancer 2015;4:163-4.
38. Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, Luca A, Del Arbol LR, Leberre MA,
Niu W, Nicholson K, Meinhardt G, Bruix J. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC:
the SPACE trial. J Hepatol 2016;64:1090-8.
39. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi
L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators. Adjuvant sorafenib for hepatocellular
carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol
2015;16:1344-54.
40. Zhong JH, Du XK, Xiang BD, Li LQ. Adjuvant sorafenib in hepatocellular carcinoma: a cautionary comment of STORM trial. World J
Hepatol 2016;8:957-60.
41. Geschwind JH, Chapiro J. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Gastroenterol Hepatol 2016;12:504-6.
42. NCT02529761. TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma. Available from: https://clinicaltrials.
gov/ct2/show/NCT02529761 [Last accessed on 18 Apr 2018].
43. NCT03097848. Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular
Carcinoma (ESCALATOR). Available from: https://clinicaltrials.gov/ct2/show/NCT03097848 [Last accessed on 18 Apr 2018].
44. NCT02436902. Adjuvant Therapies for Patients With HCC and MVI (A-TACE/S-HCC). Available from: https://clinicaltrials.gov/ct2/
show/NCT02436902 [Last accessed on 18 Apr 2018].
45. Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M,
Meinhardt G, Kang YK. Search: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with
advanced hepatocellular carcinoma. J Clin Oncol 2015;33:559-66.
46. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB. Doxorubicin plus sorafenib vs
doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010;304:2154-60.
47. Treating Advanced Hepatocellular Carcinoma in 2018. Available from: https://gicasym.org/daily-news/treating-advanced-hepatocellular-
carcinoma-2018 [Last accessed on 18 Apr 2018].
48. Abou-Elkacem L, Arns S, Brix G, Gremse F, Zopf D, Kiessling F, Lederle W. Regorafenib inhibits growth, angiogenesis, and metastasis
in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 2013;12:1322-31.
49. Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L. Regorafenib as
second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer
2013;49:3412-9.
50. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross
PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt
G, Han G. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet 2016;6736:32453-9
51. Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang
C, Sun W, Han G, Le Berre MA, Baumhauer A, Meinhardt G, Bruix J; the RESORCE Investigators. Outcomes with sorafenib (SOR)
followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): results of the international, randomized phase 3
RESORCE trial. J Clin Oncol 2017;35 suppl 4:abstr344.
52. Lorusso L, Pieruzzi L, Biagini A, Sabini E, Valerio L, Giani C, Passannanti P, Pontillo-Contillo B, Battaglia V, Mazzeo S, Molinaro E,
Elisei R. Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid
cancer. Onco Targets Ther 2016;9:6467-77.